 |
Introduction |
Most MHC class I molecules are capable of binding a
large array of individual peptides (1). In contrast, the
murine class Ib molecule, Qa-1b, predominantly binds a
single species (2, 3). We refer to this peptide as Qdm (for
Qa-1 determinant modifier; reference 2), and it is derived
from amino acids 3-11 of class Ia D-region-encoded molecules. HLA-E, which differs from Qa-1b in 55 of 181 residues in the
1 and
2 domains, binds leader peptides from
human class Ia molecules that are very similar to the murine class Ia leader peptide bound by Qa-1b (4). HLA-E
and Qa-1b, unlike other class Ia molecules, have serines
rather than the conserved residues threonine and tryptophan
at positions 143 and 147 in the "F" pocket, respectively. In
the "B" pocket, HLA-E and Qa-1b also share the key residues methionine and alanine at positions 45 and 67, respectively. The HLA-E crystal structure reveals that side chains
of five of the nine amino acids of the bound peptide protrude into the pockets of the HLA-E groove (5). Based on this structure of HLA-E, it would be predicted that only a
few substitutions in the native Qdm peptide would be tolerated for binding to Qa-1b. This use of multiple anchors
would also account for our previous finding that the Qdm
peptide binds to Qa-1b with a very high affinity (6). Here,
we test this issue by examining the ability of class I leader-
derived peptides from several mammalian species to bind
Qa-1b and define a minimum Qa-1b binding peptide. Using
surface plasmon resonance (SPR), we find that Qa-1b binds
class I leader peptides from almost all species tested. Unlike
most class Ia molecules, the binding of peptide to Qa-1b requires the retention of multiple amino acids from the native Qdm peptide sequence. The fact that this single peptide
dominates the occupancy of Qa-1b/HLA-E may also be related to the functional properties of these molecules, since
recent data show that HLA-E interacts with CD94/NKG2 receptors on NK cells to deliver an inhibitory signal (7, 8).
 |
Materials and Methods |
Cells.
Drosophila melanogaster cells (S2 cells) cultured at room temperature in Schneider's medium (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT) were cotransfected with pRMHa-3/Qa-1b truncated
(12 µg), pRMHa-3/
2-microglobulin (
2m) murine (12 µg),
and phshsneo (1µg) using the calcium-phosphate precipitation method (9).
Cloning Soluble Qa-1b for the Production of Soluble Molecules.
Total mRNA isolated from spleen cells of a C57BL/6 mouse
(RNA STAT-60; Tel-Test, Inc., Friendswood, TX) was the
template in the synthesis of first strand cDNA with reverse transcriptase (SuperScript II RT; Life Technologies, Inc.) that used
oligo(dT)12-18 as a primer. Qa-1b cDNA was synthesized by PCR
with oligonucleotides 5'-GTGAGGATGTTGCTTTTTGCCC and 5'-TCATGCCTTCTGAGGCCAGTC. The truncated Qa-1b
(consisting of the leader,
1,
2, and
3 domains with an attached [His]6-tag) cDNA was cloned into the modified vector pRMHa-3
(9). sH2-M3 was a gift from Dr. Johann Deisenhofer (University
of Texas Southwestern Medical Center at Dallas).
Production of Soluble Qa-1b.
Soluble (s)Qa-1b from the supernatant of stably transfected Drosophila cells was concentrated 10-fold, loaded onto a C10/10 column packed with 6 ml of Ni-Nta
agarose (QIAGEN Inc., Chatsworth, CA) and eluted with 150 mM imidazole (pH 7.4). The protein was further purified by ion
exchange chromatography (Mono Q; Amersham Pharmacia Biotech, Inc., Piscataway, NJ).
SPR.
All binding experiments were performed on a Biacore
2000 (Biacore International AB, Uppsala, Sweden) at 25°C. Cysteine-substituted analogue peptides of Qdm were immobilized to
the biosensor surface (Sensor Chip CM5; Biacore International
AB) using an approach similar to that described by Khilko et al.
(10). The peptides were immobilized via thioether coupling to
the biosensor flow cell, and Qa-1b was run over it in the soluble
phase. In brief, upon activation of the surface with N-hydroxylsuccinimide (NHS)-N-ethyl-N'(dimethylaminopropyl)carbodiimide (EDC), amino groups were generated by a 10-min injection
of 1 M ethylenediamine (pH 8.5; Sigma Chemical Co., St. Louis,
MO). This was followed by a 4-min introduction of reactive maleimido groups from 50 mM sulfo-SMCC (Pierce Chemical Co.,
Rockford, IL) in 25 mM sodium bicarbonate, pH 8.5. The cysteine-substituted peptide analogue QdmC5 (200 µM in 10 mM
sodium acetate, pH 5.0, except in Fig. 1, B and C, where the
QdmC5 concentration was 500 µM) was run over the biosensor
surface for 10 min. Unreacted maleimido groups were inactivated
by a 2-min exposure to 0.1 M sodium hydroxide. All immobilization steps were performed using a flow rate of 5 µl/min, except
the step in which cysteine-substituted peptides were run at 2 µl/
min. The flow rate for peptide binding experiments was 1 µl/min.

View larger version (25K):
[in this window]
[in a new window]

View larger version (14K):
[in this window]
[in a new window]

View larger version (22K):
[in this window]
[in a new window]

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 1.
Characteristics of sQa-1b/ 2m secreted from transfected D. melanogaster cells and its specific binding to immobilized QdmC5 peptide. (A)
After concentration and purification, the supernatant from Qa-1b/ 2m-transfected Drosophila cells was resolved on a 15% SDS-PAGE, and stained using
Coomassie brilliant blue. Arrows, Qa-1b heavy chain (Hc) and 2m. (B-D) SPR demonstrating binding of sQa-1b/ 2m to immobilized QdmC5. Sensorgrams were obtained using injection volumes of 20 µl at a rate of 1 µl/min. Mass increase due to macromolecular binding is measured in resonance units
(RU). Arrowheads, Start ( ) and end ( ) of the injection. (B) Injection of 0.5 µM sQa-1b or sM3. (C) 0.5 µM sQa-1b was run over the chip alone, or in
the presence of 20 µM Qdm (AMAPRTLLL), QdmC5 (AMAPCTLLL), or two control peptides, PMLTMCHAL and YPHFMPTNL. (D) 0.5 µM
sQa-1b was run at 1 µl/min for 20 min over immobilized QdmC5 in the absence or presence of competitor peptides. Results are presented as relative
binding of sQa-1b, where 0 represents binding in the presence of 20 µM Qdm (25 RU), and 1 is the binding in the absence of peptide (263 RU). *, +,
and O represent binding in the presence of 20 µM of the entire 24-mer Dd leader, MGAMAPRTL and MAPRTLLLL, respectively.
|
|
Peptide Synthesis.
Peptides were synthesized using F-MOC
chemistry on a peptide synthesizer (Synergy 432A; Applied Biosystems, Inc., Foster City, CA).
 |
Results |
We showed previously that Qa-1b predominantly binds a
single peptide species, Qdm (AMAPRTLLL; reference 3).
This result precludes our ability to identify anchor residues
by conventional techniques. Therefore, the approach used in
this investigation was to generate sQa-1b molecules and test
their binding ability to a series of related ligands using SPR.
To study antigen binding to the Qa-1b molecule, recombinant sQa-1b/
2m dimers were generated in D. melanogaster (S2) cells following established protocols (11, 12).
Truncated Qa-1b molecules secreted by stably transfected
cells were purified on Ni-coated beads followed by anion
exchange. Both heavy chain and
2m were visible on Coomassie-stained SDS-PAGE (Fig. 1 A).
Binding of Qa-1b to Immobilized Qdm Peptide Is Specific and
Concentration Dependent.
Due to the SPR limitations in
detecting the binding of small molecular weight peptides to
immobilized class I molecules, we decided to attach the
peptide to the chip. In the following experiments, we used
QdmC5 (arginine
cysteine substitution at position 5), which readily bound to the biosensor chip and in turn was
bound by sQa-1b (Fig. 1, B and C). This binding is specific,
since sM3 (Fig. 1 B) and sCD1 (not shown) failed to bind.
Binding of Qa-1b to immobilized QdmC5 was blocked by
adding QdmC5 or Qdm in solution, but not irrelevant
control peptides (YPHFMPTNL) or (PMLTMCHAL), the
latter of which contains the putative Qa-1b peptide anchors
methionine at P2 and leucine at P9 (Fig. 1 C).
Trimming and Extending Qdm at the COOH Terminus Affects Its Binding to Qa-1b.
Since peptides in solution can
compete with immobilized QdmC5 for binding to soluble
Qa-1b, we used this approach to further analyze the peptide
binding characteristics of this molecule. The Qdm nonamer peptide completely blocked binding at concentrations
between 200 nM and 20 µM (Fig. 1 D). Extending the
Qdm peptide by adding a leucine at position 10 (10-mer)
results in decreased binding relative to the nonamer at 20 and 2 µM concentrations, and almost no binding at 200 nM. Trimming the Qdm peptide at the COOH end to an 8-mer
gives a similar result. A 7-mer lost virtually all of its binding
ability. We also tested the entire 24 amino acid leader of Dd
from which the Qdm peptide is derived, and found that it
failed to block the binding of Qa-1b to immobilized peptides. Finally, we generated two more nonamers from the
leader or Dd. Instead of spanning from residues 3 to 11, these peptides span amino acids 1-9 (MGAMAPRTL) and
4-12 (MAPRTLLLL). They both failed to bind to Qa-1b.
Qa-1b Binds Peptides Derived from the Leader Segment of
Human Class I Molecules.
Since HLA-E and Qa-1b share
unique features in their peptide binding grooves, we tested
whether Qa-1b can bind the same human class I-derived
peptides that bind to HLA-E. We found that all of the
tested peptides except for the one originating from the
leader of HLA-A3 bound to Qa-1b (Fig. 2). All of the peptides that bound to both Qa-1b and HLA-E have very similar sequences that are derived from positions 3-11 of the
leader. Peptides with a threonine
methionine change at
P2 (HLA-B27, -35) bound less well, and this was more evident in experiments where the inhibiting peptides were titrated at lower concentrations (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 2.
Blocking of the binding of sQa-1b to immobilized QdmC5
by peptides derived from leader sequences of human class I molecules.
Results are presented as relative binding, where 0 is the binding of sQa-1b
in the presence of 20 µM Qdm (32 RU), and 1 is the binding in the absence of peptides (345 RU). 0.5 µM sQa-1b was run over immobilized
QdmC5 for 20 min at the rate of 1 µl/min in the presence of 20 µM
competitor peptides. For HLA-E binding, + indicates strong binding, indicates no binding, and +/ indicates weak binding. Data taken from
* Table 1 in reference 18, reference 8, and § reference 4.
|
|
MHC Class I Leader-derived Peptides from Various Mammals Bind to Qa-1b.
The unusual finding that HLA-E and
Qa-1b bind the same set of peptides, all derived from leader
sequences of MHC class I molecules, raises the possibility
that there is a conservation of similar epitopes in other
mammals. In fact, inspection of representative class Ia sequences from a variety of mammalian species reveals a conserved "Qdm-like" epitope (Table 1). We tested the ability of these putative peptides to bind to Qa-1b. Most of the
tested peptides, except those from dog or cow class I molecules, bound well to Qa-1b (Fig. 3 A). It is likely that the
presence of the positively charged arginine at P3 of the
peptide results in weaker binding.

View larger version (20K):
[in this window]
[in a new window]

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 3.
Putative peptides from leaders of various mammalian class I molecules bind to Qa-1b.
Results are presented at relative binding, where 0 is
the binding of sQa-1b in the presence of 20 µM
Qdm (25 RU in A, 26 RU in B), and 1 is the binding in the absence of blockers (276 RU in A, 230 RU in B). Running buffer was Hepes-buffered saline (HBS) in A and 2% DMSO in HBS in B.
|
|
Some of these leader peptides are extremely hydrophobic
and not soluble in aqueous solvents. One such peptide is
VMSPTVLLL, a Qdm-like epitope derived from the cat
class I leader. To circumvent this problem, we diluted the
peptide in 2% DMSO, where it remained soluble, and then
used 2% DMSO as a running buffer. Under these conditions,
we demonstrate that both the murine Qdm peptide and the
peptide derived from the cat sequence bind Qa-1b (Fig. 3 B).
The Minimal Requirements for Peptide Binding to Qa-1b.
We next determined the minimum requirement for ligand
binding to Qa-1b by synthesizing a number of peptides in
which glycines were introduced in different positions (Table 2). We used glycine instead of alanine because the native Qdm sequence contains two alanines. Of the minimal
peptides we tested, those with two or three nonglycine residues showed no (GMGGGGGGL, GMGGRGGGL) or
very little binding (GMGGGGLGL, GMGGGGGLL) (Table 2). However, a peptide with four of nine native residues GMGGGGLLL blocked >50% of binding of sQa-1b to immobilized QdmC5 peptide at the highest concentration
tested (20 µM). However, when this peptide was titrated,
we noted relatively little blocking activity at 2 µM and
none at 200 nM, in marked contrast to the titration seen
when more homologous peptides were tested (Fig. 3 A).
This indicates that methionine at P2 and the three
COOH-terminal leucines are sufficient for detectable although relatively very weak binding to Qa-1b. Side chains
of other amino acids in Qdm also play a role in the overall
peptide binding. There is apparently a fine balance in their
contribution which is dependent on the neighboring residues, since a peptide with five native residues (GMGGRGLLL) binds better to Qa-1b than a peptide with six native
residues (GMGPRGLLL).
 |
Discussion |
Both Qa-1b (3) and HLA-E (4) bind a similar peptide
derived from the leader of class Ia molecules. It appears that
these are the major peptides that both of these class I molecules bind. Although Qa-1b and HLA-E share unique residues in their F pocket that are not found in other class I molecules, it is surprising that they bind similar peptides, since
they differ considerably in their primary structure. Data
presented in this paper show that Qa-1b not only binds peptides derived from the leader of murine MHC molecules,
but also binds all of the human class I-derived peptides that
were reported to interact with HLA-E, as well as putative class I leader peptides from several other mammalian species. An examination of leader sequences from representative class
I alleles from several mammalian species shows a conservation of the Qa-1b/HLA-E binding epitope between positions
3 and 11 of the segment. In fact, among the class I-derived
peptides we tested, there is relatively little variability in most
of the amino acids. For example, P4 (proline) and P9 (leucine) had no variability, whereas P1, P2, P5, and P7 had a
single predominant residue although an alternative amino
acid was seen in some peptides. The binding of this array of
xenogeneic leader peptides was almost as efficient as the
binding of the murine leader itself. It is important to note
that leaders of Qa-1b, HLA-E, and their other mammalian
homologues are unique and do not contain the conserved
Qdm-like epitope. Consequently, the peptide binding
grooves of these molecules are not occupied by peptides
derived from their own leaders.
We have attempted to determine the minimum motif
required for peptide binding to Qa-1b. Since only one peptide has been eluted from the groove of this molecule, it is
not possible to assign anchor residues in the conventional
manner. In addition to embedding principal anchors, methionine at P2 and leucine at P9, we needed to introduce
two more wild-type residues in the polyglycine chain, leucines at P7 and P8, to observe detectable binding. However, the binding of this pentaglycine analogue was still
considerably weaker than that of native Qdm, suggesting
that side chains of other residues also contribute to the
overall interaction. Although it is possible that binding of
the minimal peptide with fewer anchor residues could have
been found had we used a backbone other than glycine (13), several other minimal peptides with glycine backbones have been used successfully to identify anchors that
participate in binding to class I molecules (14, 15).
Thus, the finding that Qdm requires multiple anchors
would explain the dominance of a single peptide in its
groove. The data presented here, together with the recent
crystal structure of HLA-E bound to its peptide (5), suggest
that Qa-1b and HLA-E can only bind Qdm-like peptides
with high efficiency. However, it cannot be ruled out that
their occupancy by these peptides is a result of a restrictive
peptide antigen processing and/or presentation pathway. It
is interesting to note that the common ligand that Qa-1b
and HLA-E bind is derived from a conserved part of class I
leader segments that are expendable in the mature protein
and thus would not affect selection for polymorphic peptide binding residues.
Boyson et al. (16) pointed out that a comparison of the
rates of synonymous and nonsynonymous nucleotide substitutions in the peptide binding region versus the remainder of the molecule indicates that the peptide binding
groove of HLA-E and its homologues in macaques has
been conserved for over 36 million years, when the two
last shared a common ancestor. Yeager et al. have communicated that, although not orthologous, Qa-1b and HLA-E
might have evolved similar functions through convergent evolution at the amino acid sequence level of the peptide
binding region (17). Regardless of whether molecular-level
convergence or evolutionary conservation of the peptide
binding region accounts for the specificity of these grooves,
this conservation of specificity suggests a crucial immunological function for these molecules. In this regard, it has
recently been shown that HLA-E is a ligand for CD94/
NKG2 receptors on NK cells; interaction of HLA-E with this receptor protects target cells from NK-mediated lysis
(7, 8). Although this has not yet been demonstrated for
Qa-1b, it is likely that it interacts with its murine CD94/
NKG2 counterpart in a similar manner. Class I molecules
in mice could, through Qa-1b, control the activity of NK
cells which would be signaled upon interaction with cell
surface-expressed Qa-1b. Decreased expression and/or
processing of class I molecules would decrease the expression of Qa-1b, which would in turn result in a changed activity level of NK cells.
It is conceivable that occasionally Qa-1b-bound class
I-derived peptides could be replaced, or that some of the
peptide binding grooves might be initially occupied by
other self- or pathogen-derived peptides which would be
presented to T cells. Future studies should show whether
Qa-1b is recognized by NK cell receptors, and what role
peptides play in the response.
Address correspondence to James Forman, Department of Microbiology, University of Texas Southwestern
Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75235-9048. Phone: 214-648-5924; Fax: 214-648-5929; E-mail: jforma{at}mednet.swmed.edu
Received for publication 13 April 1998 and in revised form 18 June 1998.
This work was supported by National Institutes of Health grants P01-AI-37818, R01-AI-34930, and 5-RO1-AI-37942 (to J. Forman), and by a Welch Foundation grant (to C.A. Hasemann).
| 1.
|
Hunt, D.F.,
R.A. Henderson,
J. Shabanowitz,
K. Sakaguchi,
H. Michel,
N. Sevilir,
A.L. Cox,
E. Appella, and
V.H. Engelhard.
1992.
Characterization of peptides bound to the class
I MHC molecule HLA-A2.1 by mass spectrometry.
Science.
255:
1261-1263
[Abstract/Free Full Text].
|
| 2.
|
Aldrich, C.J.,
A. DeCloux,
A.S. Woods,
R.J. Cotter,
M.J. Soloski, and
J. Forman.
1994.
Identification of a TAP-dependent leader peptide recognized by alloreactive T cells specific
for a class Ib antigen.
Cell.
79:
649-658
[Medline].
|
| 3.
|
DeCloux, A.,
A.S. Woods,
R.J. Cotter,
M.J. Soloski, and
J. Forman.
1997.
Dominance of a single peptide bound to the
class Ib molecule, Qa-1b.
J. Immunol.
158:
2183-2191
[Abstract].
|
| 4.
|
Braud, V.,
E.Y. Jones, and
A. McMichael.
1997.
The human
major histocompatibility complex class Ib molecule HLA-E
binds signal sequence-derived peptides with primary anchor
residues at position 2 and 9.
Eur. J. Immunol.
27:
1164-1169
[Medline].
|
| 5.
|
O'Callaghan, C.A.,
J. Tormo,
B.E. Willcox,
V.M. Braud,
B.K. Jakobsen,
D.I. Stuart,
A.J. McMichael,
J.I. Bell, and
E.Y. Jones.
1998.
Structural features impose tight peptide
binding specificity in the nonclassical MHC molecule HLA-E.
Mol. Cell.
1:
531-541
.
[Medline] |
| 6.
|
Kurepa, Z., and
J. Forman.
1997.
Peptide binding to the class
Ib molecule, Qa-1b.
J. Immunol.
158:
3244-3251
[Abstract].
|
| 7.
|
Braud, V.M.,
D.S.J. Allan,
C.A. O'Callaghan,
K. Sodestrom,
A. D'Andrea,
G.S. Ogg,
S. Lazetic,
N.T. Young,
J.I. Bell,
J.H. Phillips,
L.L. Lanier, and
A.J. McMichael.
1998.
HLA-E
binds to natural killer receptors CD94/NKG2A, B and C.
Nature.
91:
795-799
.
|
| 8.
|
Borrego, F.,
M. Ulbrecht,
E.H. Weiss,
J.E. Coligan, and
A.G. Brooks.
1998.
Recognition of human histocompatibility leukocyte antigen (HLA-A)-E complexed with HLA class
I signal sequence-derived peptides by CD94/NKG2 confers
protection from natural killer cell-mediated lysis.
J. Exp.
Med.
187:
813-818
[Abstract/Free Full Text].
|
| 9.
|
Bunch, T.A.,
Y. Grinblat, and
L.S.B. Goldstein.
1988.
Characterization and use of the Drosophila metallothionein promoter in cultured Drosophila melanogaster cells.
Nucleic Acids
Res.
16:
1043-1061
[Abstract/Free Full Text].
|
| 10.
|
Khilko, S.N.,
M. Corr,
L.F. Boyd,
A. Lees,
J.K. Inmaa, and
D.H. Margulies.
1993.
Direct detection of major histocompatibility complex class I binding to antigenic peptides using
surface plasmon resonance.
J. Biol. Chem.
268:
15425-15434
[Abstract/Free Full Text].
|
| 11.
|
Matsumura, M.,
Y. Saito,
M.R. Jackson,
E.S. Song, and
P.A. Peterson.
1992.
In vitro peptide binding to soluble empty class
I major histocompatibility complex molecules from transfected Drosophila melanogaster cells.
J. Biol. Chem.
267:
23589-23595
[Abstract/Free Full Text].
|
| 12.
|
Wang, C.R.,
A.R. Castano,
P.A. Peterson,
C. Slaughter,
K.F. Lindahl, and
J. Deisenhofer.
1995.
Nonclassical binding
of formylated peptide in crystal structure of the MHC class Ib
molecule H2-M3.
Cell.
82:
655-664
[Medline].
|
| 13.
|
Maryanski, J.L.,
A.S. Verdini,
P.C. Weber,
F.R. Salemme, and
G. Corradin.
1990.
Competitor analogs for defined T
cell antigens: peptides incorporating a putative binding motif
and polyproline or polyglycine spaces.
Cell.
60:
63-72
[Medline].
|
| 14.
|
Parker, K.C.,
M.A. Bednarek,
L.K. Hull,
U. Utz,
B. Cunningham,
H.J. Zweerink,
W.E. Biddison, and
J.E. Coligan.
1992.
Sequence motifs important for peptide binding to the
human MHC molecule, HLA-A2.
J. Immunol.
149:
3580-3587
[Abstract].
|
| 15.
|
DiBrino, M.,
K.C. Parker,
J. Shiloach,
M. Knierman,
J. Lukszo,
R.V. Turner,
W.E. Biddison, and
J.E. Coligan.
1993.
Endogenous peptides bound to HLA-A3 possess a specific
combination of anchor residues that permit identification of
potential antigenic peptides.
Proc. Natl. Acad. Sci. USA.
90:
1508-1512
[Abstract/Free Full Text].
|
| 16.
|
Boyson, J.E.,
S.N. McAdam,
A. Gallimore,
T.G. Golos,
X. Liu,
F.M. Gotch,
A.L. Hughes, and
D.I. Watkins.
1995.
The
MHC E locus in macaques is polymorphic and is conserved
between macaques and humans.
Immunogenetics.
41:
59-68
[Medline].
|
| 17.
|
Yeager, M.,
S. Kumar, and
A.L. Hughes.
1997.
Sequence
convergence in the peptide-binding region of primate and
rodent MHC class Ib molecules.
Mol. Biol. Evol.
14:
1035-1041
[Abstract].
|
| 18.
|
Braud, V.M.,
D.S.J. Allan,
D. Wilson, and
A.J. McMichael.
1997.
TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader
peptide.
Curr. Biol.
8:
1-10
.
|
| 19.
|
Crew, M.D.,
L.M. Bates,
C.A. Douglass, and
J.L. York.
1996.
Expressed Peromyscus maniculatus (Pema) MHC class I
genes: evolutionary implications and the identification of a
gene encoding a Qa1-like antigen.
Immunogenetics.
44:
177-185
[Medline].
|